ImmunoGen Announces Webcasts of Presentations at Upcoming Virtual Conferences

November 18, 2020

WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 18, 2020-- ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:

- **Piper Sandler 32nd Annual Virtual Healthcare Conference**
  November 23 at 10:00am ET

- **Evercore ISI Annual HealthCONx Conference**
  December 1 at 12:10pm ET

A webcast of each presentation will be accessible through the Investors and Media section of the Company's website, [www.immunogen.com](http://www.immunogen.com). Following the live webcast, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.”

Learn more about who we are, what we do, and how we do it at [www.immunogen.com](http://www.immunogen.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20201118005866/en/)

INVESTOR RELATIONS AND MEDIA

ImmunoGen
Courtney O’Konek
781-895-0600
courtney.okonek@immunogen.com

OR

FTI Consulting
Robert Stanislaro
212-850-5657
robert.stanislaro@fticonsulting.com

Source: ImmunoGen, Inc.